MabThera Receives Positive Opinion in Europe for Combination With Any Chemotherapy Regimen in First-Line Treatment for Follicular Non-Hodgkin's Lymphoma.

PR Newswire Europe, December, 2007

BASEL, Switzerland, December 14 /PRNewswire/ --

- Physicians Will be Able to Prescribe MabThera With Their Preferred Chemotherapy Regimen as Initial Treatment

Roche announced today that the European Union's Committee on Human Medical Products (CHMP) has given a positive recommendation for extension of the MabThera label to include use of MabThera combined with any chemotherapy combination as first-line treatment for follicular Non-Hodgkin's Lymphoma (NHL), the most common form of indolent NHL. Physicians will now be able to prescribe MabThera with their preferred chemotherapy regimen as an initial treatment for their patients.

"The positive opinion is an important step forward in expanding the availability of MabThera as first-line treatment...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement